Novo Nordisk Stock Tumbles on Post-Wegovy Plan — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk laid out a post-Wegovy growth strategy built around new drugs intended to compete with Eli Lilly, but the presentation failed to convince investors.
- Novo's shares slid as the drugmaker mapped out its path beyond the blockbuster Wegovy weight-loss franchise.
Why it matters: The selloff shows the market is unconvinced that Novo's pipeline beyond Wegovy can hold off Eli Lilly's encroachment. With Wegovy as Novo's growth engine, investors need to see credible next-wave obesity and metabolic drugs — and this strategy day did not deliver that reassurance.
Ask SkimNews
